- Home
- MHO vs ZLAB Comparison
MHO vs ZLAB Comparison
Compare MHO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHO
- ZLAB
- Stock Information
- Founded
- MHO 1976
- ZLAB 2013
- Country
- MHO United States
- ZLAB China
- Employees
- MHO N/A
- ZLAB N/A
- Industry
- MHO Homebuilding
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- MHO Consumer Discretionary
- ZLAB Health Care
- Exchange
- MHO Nasdaq
- ZLAB Nasdaq
- Market Cap
- MHO 3.2B
- ZLAB 3.4B
- IPO Year
- MHO 1986
- ZLAB 2017
- Fundamental
- Price
- MHO $116.79
- ZLAB $33.78
- Analyst Decision
- MHO Buy
- ZLAB Strong Buy
- Analyst Count
- MHO 3
- ZLAB 3
- Target Price
- MHO $176.50
- ZLAB $55.00
- AVG Volume (30 Days)
- MHO 350.9K
- ZLAB 779.4K
- Earning Date
- MHO 01-29-2025
- ZLAB 02-27-2025
- Dividend Yield
- MHO N/A
- ZLAB N/A
- EPS Growth
- MHO 21.59
- ZLAB N/A
- EPS
- MHO 19.71
- ZLAB N/A
- Revenue
- MHO $4,504,670,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- MHO $4.65
- ZLAB $49.04
- Revenue Next Year
- MHO $7.64
- ZLAB $46.80
- P/E Ratio
- MHO $5.93
- ZLAB N/A
- Revenue Growth
- MHO 11.68
- ZLAB 35.01
- 52 Week Low
- MHO $109.92
- ZLAB $13.48
- 52 Week High
- MHO $176.18
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- MHO 36.48
- ZLAB 79.95
- Support Level
- MHO $112.83
- ZLAB $30.61
- Resistance Level
- MHO $121.96
- ZLAB $33.00
- Average True Range (ATR)
- MHO 3.71
- ZLAB 1.32
- MACD
- MHO 0.26
- ZLAB 0.58
- Stochastic Oscillator
- MHO 36.23
- ZLAB 86.34
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.